J&J prices ketamine-like depression treatment at $590-$885 for two doses
Johnson & Johnson said the company’s new nasal spray depression treatment Spravato will be priced at $590 for a 56-milligram dose and $885 for an 84-milligram dosage.
Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.
Pfizer Cuts 150 Jobs, Along With Broader R&D Reconfigurations
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
7 Biotech Trends to Look Out for in 2019
Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
Impel NeuroPharma Closes $67.5 Million Series D to Advance CNS Portfolio
Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.
Mental health crisis could cost the world $16 trillion by 2030
Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.
Impatient patients turn to online ‘buyers club’ for new drugs
Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.
CDC: 14 Million Americans Will Have Alzheimer’s by 2060
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.
Lilly migraine drug wins European panel thumbs-up
A European Medicines Agency panel recommended the approval of U.S. pharmaceutical group Eli Lilly’s migraine treatment, bringing the drug one step closer to being sold in the European Union.
Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference
Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!